{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:50:40Z","timestamp":1772639440288,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangzhou Area Clinical Specialty Technology Program","award":["2023P-TS39"],"award-info":[{"award-number":["2023P-TS39"]}]},{"name":"Sun Yat-Sen Clinical Research Cultivating Program","award":["SYS-C-202007"],"award-info":[{"award-number":["SYS-C-202007"]}]},{"name":"Sun Yat-Sen Medical-industrial Integration Cultivating Program","award":["YXYGRH202203"],"award-info":[{"award-number":["YXYGRH202203"]}]},{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","award":["20221078"],"award-info":[{"award-number":["20221078"]}],"id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11064-025-04646-x","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T01:36:32Z","timestamp":1767490592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Valproate Releases the Latent Differentiation Capacity of Neuroblastoma by Targeting SP1\/CDK4 Signaling"],"prefix":"10.1007","volume":"51","author":[{"given":"Mingwei","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xilin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-5847","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"4","key":"4646_CR1","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein R, P\u00f6tschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN) (2017) Busulfan and Melphalan versus carboplatin, etoposide, and Melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 18(4):500\u2013514","journal-title":"Lancet Oncol"},{"issue":"24","key":"4646_CR2","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/cncr.30934","volume":"123","author":"WB London","year":"2017","unstructured":"London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR (2017) Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on children\u2019s oncology group early-phase trials. Cancer 123(24):4914\u20134923","journal-title":"Cancer"},{"issue":"6127","key":"4646_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546\u20131558","journal-title":"Science"},{"issue":"10","key":"4646_CR4","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","volume":"17","author":"M Romoli","year":"2019","unstructured":"Romoli M, Mazzocchetti P, D\u2019Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C (2019) Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol 17(10):926\u2013946","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"4646_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, L\u00fcbbert M, H\u00e4nel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, D\u00f6hner K, Sauer M, Ganser A, Amadori S, Mandelli F, D\u00f6hner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano malattie ematologiche dell\u2019Adulto; German-Austrian acute myeloid leukemia study Group; study alliance leukemia (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"9","key":"4646_CR6","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bcp.2005.02.003","volume":"69","author":"JL Armstrong","year":"2005","unstructured":"Armstrong JL, Redfern CP, Veal GJ (2005) 13-cis retinoic acid and isomerisation in paediatric oncology\u2013is changing shape the key to success? Biochem Pharmacol 69(9):1299\u20131306","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4646_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0006-291X(03)00177-3","volume":"302","author":"T Nguyen","year":"2003","unstructured":"Nguyen T, Hocker JE, Thomas W, Smith SA, Norris MD, Haber M, Cheung B, Marshall GM (2003) Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res Commun 302(3):462\u2013468","journal-title":"Biochem Biophys Res Commun"},{"key":"4646_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","volume":"6","author":"XH Tang","year":"2011","unstructured":"Tang XH, Gudas LJ (2011) Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 6:345\u2013364","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"4646_CR9","doi-asserted-by":"publisher","first-page":"a014415","DOI":"10.1101\/cshperspect.a014415","volume":"3","author":"M Huang","year":"2013","unstructured":"Huang M, Weiss WA (2013) Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3(10):a014415","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"4646_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/genes8040113","volume":"8","author":"MV Ruiz-P\u00e9rez","year":"2017","unstructured":"Ruiz-P\u00e9rez MV, Henley AB, Arsenian-Henriksson M (2017) The MYCN protein in health and disease. Genes (Basel) 8(4):113","journal-title":"Genes (Basel)"},{"issue":"1","key":"4646_CR11","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1038\/s41467-024-47945-7","volume":"15","author":"IM Saldana-Guerrero","year":"2024","unstructured":"Saldana-Guerrero IM, Montano-Gutierrez LF, Boswell K, Hafemeister C, Poon E, Shaw LE, Stavish D, Lea RA, Wernig-Zorc S, Bozsaky E, Fetahu IS, Zoescher P, P\u00f6tschger U, Bernkopf M, Wenninger-Weinzierl A, Sturtzel C, Souilhol C, Tarelli S, Shoeb MR, Bozatzi P, Rados M, Guarini M, Buri MC, Weninger W, Putz EM, Huang M, Ladenstein R, Andrews PW, Barbaric I, Cresswell GD, Bryant HE, Distel M, Chesler L, Taschner-Mandl S, Farlik M, Tsakiridis A, Halbritter F (2024) A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations. Nat Commun 15(1):3745","journal-title":"Nat Commun"},{"issue":"6","key":"4646_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/neuonc\/noab241","volume":"24","author":"Z Weng","year":"2022","unstructured":"Weng Z, Lin J, He J, Gao L, Lin S, Tsang LL, Zhang H, He X, Wang G, Yang X, Zhou H, Zhao H, Li G, Zou L, Jiang X (2022) Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma. Neuro Oncol 24(6):872\u2013885","journal-title":"Neuro Oncol"},{"issue":"10","key":"4646_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16(10):695\u2013714","journal-title":"CNS Drugs"},{"issue":"24","key":"4646_CR14","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969\u20136978","journal-title":"EMBO J"},{"key":"4646_CR15","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.phrs.2020.104786","volume":"156","author":"F Cucchiara","year":"2020","unstructured":"Cucchiara F, Pasqualetti F, Giorgi FS, Danesi R, Bocci G (2020) Epileptogenesis and oncogenesis: an antineoplastic role for antiepileptic drugs in brain tumours? Pharmacol Res 156:104786","journal-title":"Pharmacol Res"},{"issue":"1","key":"4646_CR16","first-page":"97","volume":"20","author":"J Cinatl Jr","year":"2002","unstructured":"Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J (2002) Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 20(1):97\u2013106","journal-title":"Int J Oncol"},{"issue":"3","key":"4646_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/pbc.22839","volume":"56","author":"WL Hobbie","year":"2011","unstructured":"Hobbie WL, Mostoufi SM, Carlson CA, Gruccio D, Ginsberg JP (2011) Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer 56(3):474\u2013476","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"4646_CR18","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1111\/bph.12846","volume":"171","author":"P Sonawane","year":"2014","unstructured":"Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH (2014) Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol 171(23):5330\u20135344","journal-title":"Br J Pharmacol"},{"key":"4646_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.omto.2021.09.004","volume":"23","author":"S Alleboina","year":"2021","unstructured":"Alleboina S, Aljouda N, Miller M, Freeman KW (2021) Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor. Mol Ther Oncolytics 23:181\u2013191","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"4646_CR20","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1007\/s12035-022-02949-6","volume":"59","author":"MM Khazeem","year":"2022","unstructured":"Khazeem MM, Casement JW, Schlossmacher G, Kenneth NS, Sumbung NK, Chan JYT, McGow JF, Cowell IG, Austin CA (2022) TOP2B is required to maintain the adrenergic neural phenotype and for ATRA-Induced differentiation of SH-SY5Y neuroblastoma cells. Mol Neurobiol 59(10):5987\u20136008","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4646_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/ijms19010132","volume":"19","author":"P Chlapek","year":"2018","unstructured":"Chlapek P, Slavikova V, Mazanek P, Sterba J, Veselska R (2018) Why differentiation therapy sometimes fails: molecular mechanisms of resistance to retinoids. Int J Mol Sci 19(1):132","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4646_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrn2097","volume":"8","author":"C Dehay","year":"2007","unstructured":"Dehay C, Kennedy H (2007) Cell-cycle control and cortical development. Nat Rev Neurosci 8(6):438\u2013450","journal-title":"Nat Rev Neurosci"},{"key":"4646_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tcb.2010.01.006","volume":"20","author":"P Salomoni","year":"2010","unstructured":"Salomoni P, Calegari F (2010) Cell cycle control of mammalian neural stem cells: putting a speed limit on G1. Trends Cell Biol 20:233\u2013243","journal-title":"Trends Cell Biol"},{"issue":"10","key":"4646_CR24","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.4161\/cc.9.10.11598","volume":"9","author":"C Lange","year":"2010","unstructured":"Lange C, Calegari F (2010) Cdks and cyclins link G1 length and differentiation of embryonic, neural and hematopoietic stem cells. Cell Cycle 9(10):1893\u20131900","journal-title":"Cell Cycle"},{"issue":"2","key":"4646_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrg2269","volume":"9","author":"KW Orford","year":"2008","unstructured":"Orford KW, Scadden DT (2008) Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 9(2):115\u2013128","journal-title":"Nat Rev Genet"},{"issue":"2","key":"4646_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2009.07.003","volume":"5","author":"AM Singh","year":"2009","unstructured":"Singh AM, Dalton S (2009) The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell 5(2):141\u2013149","journal-title":"Cell Stem Cell"},{"issue":"3","key":"4646_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.stem.2009.05.026","volume":"5","author":"C Lange","year":"2009","unstructured":"Lange C, Huttner WB, Calegari F (2009) Cdk4\/cyclinD1 overexpression in neural stem cells shortens G1, delays neurogenesis, and promotes the generation and expansion of basal progenitors. Cell Stem Cell 5(3):320\u2013331","journal-title":"Cell Stem Cell"},{"issue":"4","key":"4646_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0092-8674(91)90100-D","volume":"65","author":"Y Xiong","year":"1991","unstructured":"Xiong Y, Connolly T, Futcher B, Beach D (1991) Human D-type Cyclin. Cell 65(4):691\u2013699","journal-title":"Cell"},{"key":"4646_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.18632\/genesandcancer.221","volume":"13","author":"SJ Baker","year":"2022","unstructured":"Baker SJ, Poulikakos PI, Irie HY, Parekh S, Reddy EP (2022) CDK4: a master regulator of the cell cycle and its role in cancer. Genes Cancer 13:21\u201345","journal-title":"Genes Cancer"},{"key":"4646_CR30","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1523\/JNEUROSCI.15-09-06046.1995","volume":"15","author":"T Takahashi","year":"1995","unstructured":"Takahashi T, Nowakowski RS, Caviness VS (1995) The cell cycle of the pseudostratified ventricular epithelium of the embryonic murine cerebral wall. J Neurosci 15:6046\u20136057","journal-title":"J Neurosci"},{"issue":"7","key":"4646_CR31","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/stem.1114","volume":"30","author":"S Lim","year":"2012","unstructured":"Lim S, Kaldis P (2012) Loss of Cdk2 and Cdk4 induces a switch from proliferation to differentiation in neural stem cells. Stem Cells 30(7):1509\u20131520","journal-title":"Stem Cells"},{"issue":"5","key":"4646_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1084\/jem.20102167","volume":"208","author":"B Artegiani","year":"2011","unstructured":"Artegiani B, Lindemann D, Calegari F (2011) Overexpression of cdk4 and cyclinD1 triggers greater expansion of neural stem cells in the adult mouse brain. J Exp Med 208(5):937\u2013948","journal-title":"J Exp Med"},{"issue":"4","key":"4646_CR33","first-page":"513","volume":"89","author":"L O\u2019Connor","year":"2016","unstructured":"O\u2019Connor L, Gilmour J, Bonifer C (2016) The role of the ubiquitously expressed transcription factor Sp1 in Tissue-specific transcriptional regulation and in disease. Yale J Biol Med 89(4):513\u2013525","journal-title":"Yale J Biol Med"},{"issue":"2","key":"4646_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/febs.13148","volume":"282","author":"K Beishline","year":"2015","unstructured":"Beishline K, Azizkhan-Clifford J (2015) Sp1 and the \u2018hallmarks of cancer\u2019. FEBS J 282(2):224\u2013258","journal-title":"FEBS J"},{"issue":"35","key":"4646_CR35","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1038\/onc.2011.568","volume":"31","author":"TI Hsu","year":"2012","unstructured":"Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC, Hung JJ (2012) Sp1 expression regulates lung tumor progression. Oncogene 31(35):3973\u20133988","journal-title":"Oncogene"},{"issue":"1","key":"4646_CR36","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1038\/s41598-019-42501-6","volume":"9","author":"IK Kim","year":"2019","unstructured":"Kim IK, Lee YS, Kim HS, Dong SM, Park JS, Yoon DS (2019) Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via Lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma. Sci Rep 9(1):5933","journal-title":"Sci Rep"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-025-04646-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:12:08Z","timestamp":1772619128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-025-04646-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4646"],"URL":"https:\/\/doi.org\/10.1007\/s11064-025-04646-x","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version revised due to addition of equal contribution.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28"}}